Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Equities researchers at Wedbush lifted their Q1 2023 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a research note issued on Wednesday, April 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.34) for the quarter, up […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 16,730,000 shares, a decline of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily volume of 2,760,000 shares, the […]
Dupont Capital Management Corp lowered its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) by 56.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,727 shares of the company’s stock after selling 29,675 shares during the period. Dupont Capital Management Corp’s holdings […]